| Autor: |
Ngwe Tun MM; Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.; Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University, Izumo 690-8504, Japan., Kyaw AK; Department of Medical Research, Ministry of Health, Yangon 11191, Myanmar., Nwe KM; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan., Myaing SS; Department of Medical Research, Ministry of Health, Yangon 11191, Myanmar., Win YT; 550-Bedded Children Hospital (Mandalay), Department of Medical Services, Ministry of Health, Mandalay City 05021, Myanmar., Inoue S; Kenya Research Station, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan., Takamatsu Y; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan., Urano T; Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University, Izumo 690-8504, Japan., Thu HM; Department of Medical Research, Ministry of Health, Yangon 11191, Myanmar., Hmone SW; Department of Pathology, University of Medicine-1, Ministry of Health, Yangon 11131, Myanmar., Thant KZ; Myanmar Academy of Medical Science, Yangon 11201, Myanmar., Morita K; Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.; Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.; DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki 852-8523, Japan. |
| Abstrakt: |
Chikungunya virus (CHIKV) infection is a re-emerging arboviral disease with no approved vaccine, although numerous options are in development. Before vaccine implementation, disease burden, affected age group, and hospitalization rate information should be documented. In 2019, a sizeable outbreak of the East Central South African genotype of CHIKV occurred in Myanmar, and during this period, a cross-sectional study was conducted in two regions, Mandalay and Yangon, to examine the molecular and seropositivity rate of the CHIKV infection. The participants (1124) included dengue-suspected pediatric patients, blood donors, and healthy volunteers, who were assessed using molecular assays (quantitative real-time RT-PCR), serological tests (anti-CHIKV IgM capture and IgG indirect enzyme-linked immunosorbent assays), and neutralization tests. The tests confirmed the following positivity rates: 11.3% (127/1124) for the molecular assay, 12.4% (139/1124) for the anti-CHIKV IgM Ab, 44.5% (500/1124) for the anti-CHIKV IgG Ab, and 46.3% (520/1124) for the CHIKV neutralizing Ab. The highest rate for the molecular test occurred with the dengue-suspected pediatric patients. The seroprevalence rate through natural infection was higher in the healthy volunteers and blood donors than that in the pediatric patients. The results of this study will help stakeholders determine the criteria for choosing appropriate recipients when a CHIKV vaccine is introduced in Myanmar. |
